Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy

Journal of Hepatology

Volumn 29, Issue 1, 1998, Pages 151-168

  Zoulim, Fabien ^a,b   Trépo, Christian ^a  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAMCICLOVIR; LAMIVUDINE; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; DRUG DESIGN; DRUG EFFICACY; GENE MUTATION; GENE STRUCTURE; HEPATITIS B; HEPATITIS B VIRUS; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0032125193     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80191-8     Document Type: Review

References (149)

1. Carithers RL. Effect of interferon on hepatitis B. Lancet. 351:1998;157.
2. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
3. Trépo C, Jezek P, Atkinson G, Boon R. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. [abstract] Hepatology. 24:1996;188.
4. Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
5. Fontana RJ, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology. 26:1997;234-237.
6. Summers J. Three recently described animal virus models for human hepatitis B virus. Hepatology. 1:1981;179-183.
7. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell. 29:1982;403-415.
8. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science. 232:1986;477-484.
9. Tuttleman J, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell. 47:1986;451-460.
10. Schaller H, Fischer M. Transcriptional control of hepadnavirus gene expression. Mason WS, Seeger C. Current Topics in Microbiology and Immunology. Hepadnaviruses. Molecular Biology and Pathogenesis. 1991;41-60 Springer-Verlag, Berlin.
11. Kay A, Mandart E, Trepo C, Galibert F. The HBV HBx gene expressed in E. coli is recognised by sera from hepatitis patients. EMBO J. 4:1985;1287-1292.
12. Kuroki K, Cheung R, Marion P, Ganem D. A cell surface protein that binds avian hepatitis B virus particles. J Virol. 68:1994;2091-2096.
13. Mason W. The problem of antiviral therapy for chronic hepadnavirus infection. J Hepatol. 17:1993;137-142. (Suppl. 3).
14. Seeger C, Mason W. Hepadnavirus replication and approaches to antiviral therapy. Doerfler W, Bohm P. Virus Strategies. 1993;77-93 VCH, Germany.
15. Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature. 305:1983;827-829.
16. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNAseH activity. J Virol. 64:1990;613-620.
17. Chang L-J, Hirsch RC, Ganem D, Varmus HE. Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J Virol. 64:1990;5553-5558.
18. Roychoudhury S, Faruqi AF, Shih C. Pregenomic RNA encapsidation analysis of eleven missense and nonsense polymerase mutants of human hepatitis B virus. J Virol. 65:1991;3617-3624.
19. Wu T-T, Condreay LD, Coates L, C Aldrich, Mason WS. Evidence that less-than-full-length pol gene products are functional in hepadnavirus DNA synthesis. J Virol. 65:1991;2155-2163.
20. Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol. 68:1994;6-13.
21. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution if HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
22. Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. Int Antiviral News. 5:1997;123-124.
23. Seeger C, Leber EH, Wiens LK, Hu J. Mutagenesis of a hepatitis B virus reverse transcriptase yields temperature-sensitive virus. Virology. 222:1996;430-439.
24. Wang GH, Seeger C. The reverse transcriptase of hepatitis B virus acts a protein primer fo viral DNA synthesis. Cell. 71:1992;663-670.
25. Wang GH, Seeger C. A novel mechanism for reverse transcription in hepatitis B viruses. J Virol. 67:1993;6507-6512.
26. Hu J, Toft D, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J. 16:1997;59-68.
27. Hu J, Seeger C. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci USA. 93:1996;1060-1064.
28. Wang G, Zoulim F, Leber E, Kitson J, Seeger C. The role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses. J Virol. 68:1994;8437-8442.
29. Wu T-T, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology. 175:1990;255-261.
30. Fourel I, Saputelli J, Schaffer P, Mason W. The carbocyclic analog of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J Virol. 68:1994;1059-1065.
31. Fourel I, Cullen J, Saputelli J, Aldrich C, Schaffer P, Averett D, et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol. 68:1994;8321-8330.
32. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol. 71:1997;9392-9399.
33. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 93:1996;4398-4402.
34. Hantz O, Borel C, Trabaud C, Zoulim F, Dessolin J, Camplo M, et al. Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. Antimicrob Agents Chemother. 41:1997;2579-2581.
35. Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J. 11:1992;3413-3420.
36. Nassal M. The arginine rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive strand DNA synthesis but not for virus assembly. J Virol. 66:1992;4107-4116.
37. Hirsch RC, Lavine JE, Chang LJ, Varmus HE, Ganem D. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription. Nature. 344:1990;552-555.
38. Hirsch RC, Loeb DD, Pollack JR, Ganem D. Cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J Virol. 65:1991;3309-3316.
39. Hino O, Ohtake K, Rogler CE. Features of two hepatitis B virus (HBV) DNA integrations suggest mechanism of HBV integration. J Virol. 63:1989;2638-2643.
40. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci USA. 88:1991;1059-1063.
41. Bruss V, Thomssen R. Mapping of a region of the large envelope protein required for hepatitis B virion maturation. J Virol. 68:1994;1643-1650.
42. Bruss V, Vieluf K. Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. J Virol. 69:1995;6652-6657.
43. Bruss V. A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. J Virol. 71:1997;9350-9357.
44. Schek N, Fisher M, Schaller H. The hepadnaviral X protein. McLahlan A. Molecular Biology of the Hepatitis B Virus. 1991;181-192 CRC Press, Florida.
45. Chen HS, Kaneko S, Girones R, Anderson RW, Hornbuckle WE, Tennant BC, et al. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol. 67:1993;1218-1226.
46. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral replication in vivo. J Virol. 68:1994;2026-2030.
47. Sells MA, Zelent AZ, Shvartsman M, Acs G. Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol. 62:1988;2836-2844.
48. Sells MA, Chen M, Acs G. Production of hepatitis B virus particles in hepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA. 84:1987;1005-1009.
49. Aldrich CE, Coates L, Wu T-T, Newbold J, Tennant BC, Summers J, et al. In vitro infection of woodchuck hepatocytes with woodchuck hepatitis virus and ground squirrel hepatitis virus. Virology. 172:1989;247-252.
50. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, et al. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. J Virol. 62:1988;4136-4143.
51. Tuttleman JS, Pugh JC, Summers JW. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J Virol. 58:1986;17-25.
52. Chisari F. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology. 22:1995;1316-1325.
53. Nair V, Jahnke T. Antiviral activities of isomeric dideoxynucleosides of D- and L-related stereocheistry. Antimicrob Agents Chemother. 39:1995;1017-1029.
54. Bridges E, Cheng Y. Use of novel β-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Boyer JL, Ockner RK. Progress in Liver Diseases. 13:1995;231-245.
55. Doong S-L, Tsai C-H, Schinazi RF, Liotta DC, Cheng Y-C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA. 88:1991;8495-8499.
56. Chang C-N, Doong S-L, Zhou JH, Beach JW, Jeong LS, Chu CK, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±) 2′,3′ dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem. 267:1992;13938-13942.
57. Van Draanen N, Tisdale M, Parry N, Jansen R, Dornsife R, Tuttle J, et al. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob Agents Chemother. 38:1994;868-871.
58. Severini A, Liu X-Y, Wilson J, Tyrell D. Mechanisms of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thyacytidine. Antimicrob Agents Chemother. 39:1995;1430-1435.
59. Zoulim F, Dannaoui E, Borel C, Hantz O, Lin T, Liu S, et al. 2′,3′-dideoxy-β-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother. 40:1996;448-453.
60. Parker W, Cheng Y. Mitochondrial toxicity of antiviral nucleoside analogs. J NIH Res. 6:1994;57-61.
61. Cui L, Yoon S, Schinazi R, Sommadossi J. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human. J Clin Invest. 95:1995;555-563.
62. Pai S, Liu S, Zhu Y, Chu C, Cheng Y. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyl uracil. Antimicrob Agents Chemother. 40:1996;380-386.
63. McKenzie R, Fried M, Sallie R, Conjeevaram H, Di Bisceglie A, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 333:1995;1099-1105.
64. Wang J, Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother. 40:1996;1555-1557.
65. Lewis W, Levine E, Griniuvene B, Tankersley K, Colacino J, Sommadossi J, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA. 93:1996;3592-3597.
66. Boyd M, Bacon T, Sutton D, Cole M. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother. 31:1987;1238-1242.
67. Vere Hodge R, Perkins R. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother. 33:1989;223-229.
68. Earnshaw D, Bacon T, Darlison S, Edmonds K, Perkins R, Vere Hodge R. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and Varicella-Zoster virus. Antimicrob Agents Chemother. 36:1992;2747-2757.
69. Lin E, Luscombe C, Wang Y, Shaw T, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 40:1996;413-418.
70. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother. 38:1994;719-723.
71. Tsiquaye K, Slomka M, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol. 42:1994;306-310.
72. Korba B, Boyd M. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother. 40:1996;1282-1284.
73. Tsiquaye K, Sutton D, Maung M, Boyd M. Antiviral activities and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B virus. Antivir Chem Chemother. 7:1996;153-159.
74. Shaw T, Mok S, Locarnini S. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology. 24:1996;996-1002.
75. Dannaoui E, Trépo C, Zoulim F. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antivir Chem Chemother. 8:1997;38-46.
76. Lai C-L, Ching C-K, Tung AK-M, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in chinese hepatitis B surface antigen carriers a placebo-controlled trial. Hepatology. 25:1997;241-244.
77. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study. Gastroenterology. 113:1997;1258-1263.
78. Dienstag JL, Schiff ER, Mitchell M, Gitlin N, Lisoos T, Condreay L, et al. Extended lamivudine retreatment for chronic hepatitis B. [abstract] Hepatology. 24:1996;188.
79. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver. 17:1997;103-106.
80. Lai CL, Law YF, Leung NWY, Deslauriers M, Bernard J, Sanathanan L, et al. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence and correlation with disease parameters. [abstract] Hepatology. 26:1997;522. (4Pt2).
81. Leung NWY, Lai CL, Liaw YF, Chang TT, Guan R, Tai DI, et al. Lamivudine (100 mg od) for one year significantly improves necroinflammatory activity and reduces progression in fibrosis stage: results of a placebo controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection. [abstract] Hepatology. 26:1997;916. (4Pt2).
82. Gish R, Lau J, Brooks L, Fang J, Steady S, Imperial J, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology. 23:1996;1-7.
83. Perillo R, Rakela J, Martin P, Levy G, Schiff E, Wright T, et al. Long-term lamivudine therapy of patients with recurrent hepatitis B post-liver transplantation. [abstract] Hepatology. 26:1997;196.
84. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs A, Rolles K, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 348:1996;1212-1215.
85. Perillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre-/post-liver transplantation (OLT). [abstract] Hepatology. 26:1997;526.
86. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of Lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med. 125:1996;705-712.
87. Main J, Brown J, Howells C, Galassini R, Crossey M, Karayiannis P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat. 3:1996;211-215.
88. Krüger M, Tillmann H, Trautwein C, Oldhafer K, Boker K, Pichlmayr R, et al. Famciclovir treatment of hepatitis B virus recurrence after orthotopic liver transplantation. A pilot study. [abstract] Hepatology. 22:1995;219A. (abstract 449).
89. Neuhaus P, Manns M, Atkinson G. Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B in liver transplant recipients. [abstract] Hepatology. 26:1997;528. (4Pt2).
90. Saltzman R, Jarewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 38:1994;2454-2457.
91. Krüger M, Böker KHW, Zeidler H, Manns M. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol. 26:1997;935-939.
92. Tong S, Li J, Vivitski L, Trépo C. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology. 176:1990;596-603.
93. Carman W, Hadziyannis S, McGarvey MJ, Jacyna M, Karayiannis P, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. ii:1989;588-591.
94. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trépo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol. 48:1996;8-16.
95. Brunetto M, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology. 105:1993;845-850.
96. Aguesse-Germon S, Liu SH, Chevallier M, Pichoud C, Jamard C, Borel C, et al. Inhibitory effect of 2′-fluoro-5-methyl-β-L-arabinofuranosyl-uracyl on duck hepatitis B virus replication. Antimicrob Agents Chemother. 42:1998;369-376.
97. Fourel I, Li JS, Hantz O, Jacquet C, Fox JJ, Trépo C. Effects of 2′-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and in liver of chronically infected ducks. J Med Virol. 37:1992;122-126.
98. Mason W, Cullen J, Saputelli J, Wu T, Liu C, London W, et al. Characterization of the antiviral activity of 2′ carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology. 19:1994;398-411.
99. Luscombe C, Pedersen J, E Uren, Locarnini S. Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect of intrahepatic-viral DNA, RNA, and protein expression. Hepatology. 24:1996;766-773.
100. Honkoop P, De Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet. 346:1995;1156-1157.
101. Cirelli R, Herne K, McCrary M, Lee P, Tyring S. Famciclovir : review of clinical efficacy and safety. Antiviral Res. 29:1996;141-151.
102. Honkoop P, de Man RA, Scholte HR, Zondervan PE, Van Den Berg JWO, Rademekers LHPM, et al. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology. 26:1997;211-215.
103. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
104. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
105. Richman DD. Drug resistance and its implications in the management of HIV infection. Antiviral Ther. 2:1997;41-58. (Suppl 4).
106. Arts E, Wainberg M. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother. 40:1996;527-540.
107. Locarnini SA, Aye TT, Shaw T, De Man R, Angus PW, McCaughan GW, et al. The emergence of famciclovir resistant mutations in the hepatitis B virus polymerase during therapy following liver transplantation. [abstract] Hepatology. 26:1997;A958. (4Pt2).
108. Shields PL, Ling R, Harrison T, Boxall E, Elias E, Mutimer DJ. Management and outcome of lamivudine resistant hepatitis B virus infection after liver transplantation. [abstract] Hepatology. 26:1997;A527. (4Pt2).
109. Honkoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J Hepatol. 26:1997;1393-1395.
110. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 26:1997;1148-1153.
111. Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus and development of resistance. Intervirology. 1997;. in press.
112. Tillmann HL, Trautwein C, Bock T, Glowenka M, Krüger M, Böker K, et al. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. [abstract] Hepatology. 26:1997;A1202. (4Pt2).
113. Zoulim F, Pichoud C, Wang Z, Aguesse-Germon S, Trépo C. Hepatitis B virus genome variability during famciclovir therapy. Hepatology. 26:1997;A1200. (4Pt2).
114. Norder H, Couroucé A-M, Magnius L. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 198:1994;489-503.
115. Carman W. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 4:1997;11-20. (suppl. 1).
116. Chang L-J, Pryciak P, Ganem D, Varmus HE. Biosynthesis of the reverse transcriptase of hepatitis B viruses involves de novo translation initiation not ribosomal frameshifting. Nature. 337:1989;364-368.
117. Schlicht HJ, Radziwill G, Schaller H. Synthesis and encapsidation of duck hepatitis B virus reverse transcriptase do not require formation of core-polymerase fusion proteins. Cell. 56:1989;85-92.
118. Lanford R, Notvall L, Beames B. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J Virol. 69:1995;4431-4439.
119. Xiong Y, Eickbush T. Origin and evolution of retroelements based upon their reverse transcriptase sequence. EMBO J. 9:1990;3353-3362.
120. Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 37:1993;875-881.
121. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resitant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 90:1993;5653-5656.
122. Bartholomew M, Jansen R, Jeffers L, Reddy K, Johnson L, Bunzendahl H, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 349:1997;20-22.
123. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, et al. Line Probe Assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 41:1997;284-291.
124. Allen MI, Deslauriers M, Andrews CW, Baldanti F, Tipples GA, Walters KA, et al. Identification and biologic characterization of mutations in HBV resistant to lamivudine. [abstract] Hepatology. 26:1997;A1208. (4Pt2).
125. Fischer KP, Tyrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine((-)-β-L-2′,3′-dideoxy-3′-thiacytidine) in vitro. Antimicrob Agents Chemother. 40:1996;1957-1960.
126. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants induced by associated 3TC and famciclovir administration are replication defective. Hepatology. 26:1997;A959. (4Pt2).
127. Back NKT, Berkhout B. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 41:1997;2484-2491.
128. Xiong X, Flores C, Gibbs C, Toole J. Lack of cross-resistance to PMEA for human hepatitis B DNA polymerases which express Lamivudine resistance codons. [abstract] Hepatology. 26:1997;A1211. (4Pt2).
129. Zoulim F. Improving hepatitis B virus therapy-new inhibitors of reverse transcriptase. Int Antiviral News. 5:1997;110-112.
130. Aguesse S, Dannaoui E, Wang Z, Boulay A, Borel C, Schinazi R, et al. An in vitro assay for the determination of the mechanism of inhibition of hepatitis B virus replication by nucleoside analogs and non nucleoside inhibitors. Proceedings of the IX Triennal International Symposium of Viral Hepatitis and Liver Disease. 1996;. in press.
131. Chu C, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai S, et al. Use of 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother. 39:1995;979-981.
132. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 26:1997;216-225.
133. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 41:1997;1444-1448.
134. Condreay L, Condreay J, Jansen R, Paff M, Averett DF. (-)-cis-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl) cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. Antimicrob Agents Chemother. 40:1996;520-523.
135. Bloomer J, Chan R, Sherman M, Ingraham P, DeHertog D. A preliminary study of Lobucavir for chronic hepatitis B. [abstract] Hepatology. 26:1997;A1199. (4Pt2).
136. Marinos G, Naoumov N, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology. 24:1996;991-995.
137. Gilles P, Fey G, Chisari F. Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol. 66:1992;3955-3960.
138. Guilhot S, L Guidotti, Chisari F. Interluekin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J Virol. 67:1993;7444-7449.
139. Cavanaugh VJ, Guidotti L, Chisari FV. Interleukine-12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 71:1997;3236-3243.
140. Kajino K, Jilbert A, Saputelli J, Aldrich C, Cullen J, Mason W. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J Virol. 68:1994;5792-5803.
141. Koziel MG, Liang TJ. DNA vaccines and viral hepatitis: are we going around in circles? Gastroenterology. 112:1997;1410-1414.
142. Mancini M, Hadchouel M, Tiollais P, Pourcel C, Michel M. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse to HBsAg" J Med Virol. 39:1992;67-74.
143. Pol S, Driss F, Michel M, Nalpas B, Berthelot P, Bréchot C. Specific vaccine therapy in chronic hepatitis B infection. Lancet. 344:1994;342.
144. Schirmbeck R, Bohm W, Ando K, Chisari F, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol. 69:1995;5929-2934.
145. Geissler M, Tokushige K, Chante CC, Zurawski VR, Wands JR. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA based immunization. Gastroenterology. 112:1997;1307-1320.
146. von Weizsäcker G, Wieland S, Köck J, Offensperger W-B, Offensperger S, Moradpour D, et al. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology. 26:1997;251-255.
147. Offensperger W, Offensperger S, Walter E, Teubner K, Igloi G, Blum H, et al. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. 12:1993;1257-1262.
148. Scaglioni P, Melegari M, Takahashi M, Roy Chowdhury J, Wands J. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology. 24:1996;1010-1017.
149. von Weizsäcker F, Blum H, Wands F. Cleavage of hepatitis B virus RNA by three ribozymes transcribed from single DNA template. Biochem Biophys Res Comm. 189:1992;743-748.